Mainstream

Novartis Beats Q4 Top Line And Bottom Line Estimates; Initiates Fy25 Soft Outlook

Novartis beats Q4 top-line and bottom-line estimates; initiates FY25 soft outlook

Novartis beats Q4 top-line and bottom-line estimates; initiates FY25 soft outlook

Post Contentnvs, nvsefRead More

You might also be interested in reading SIDUS HEROES Receives Investment From Animoca Brands, Alameda Research, Bloktopia, OKEX, Polygon and Master Ventures.

January 31, 2025
In Mainstream